HL

ASCO 2018 | Final analysis of the AHL2011 LYSA study

Sara Valente , Jun 21, 2018 , Expert Opinion

CLL/SLL

ASCO 2018 | Ibrutinib plus venetoclax shows promising efficacy in CLL

Sara Valente , Jun 12, 2018 , Expert Opinion

WM

ASCO 2018 | Acalabrutinib monotherapy demonstrated good efficacy in WM

Sara Valente , Jun 12, 2018

FL

ASCO 2018 | Phase III RELEVANCE study compares R2 to R-Chemo

Sara Valente , Jun 12, 2018 , Expert Opinion

DLBCL

ASCO 2018 | Durable responses seen in large B-cell lymphoma patients treated with Axi-Cel

Sara Valente , Jun 11, 2018

CLL/SLL

William Wierda | ASCO 2018 | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial

Sara Valente , Jun 8, 2018

English & Spanish

DLBCL

Raul Cordoba | ASCO 2018 | Tailoring therapy for aged patients with aggressive lymphoma

Sara Valente Natasha Fort , Jun 8, 2018

HL

Joseph Connors | ASCO 2018 | Risk-adapted treatment strategies for advanced-stage HL

Sara Valente , Jun 8, 2018

FL

Nathan Fowler | ASCO 2018 | Key findings of the phase III RELEVANCE trial in FL

Nathan Fowler , Jun 8, 2018

CLL/SLL

Susan O'Brien | ASCO 2018 | What is the role of chemo-immunotherapy in CLL?

Susan O'Brien , Jun 8, 2018